deferiprone has been researched along with Fibrosis in 4 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferiprone treatment tended to decrease muscle iron levels in mdx mice (-30%, P < 0." | 1.72 | Iron overload and impaired iron handling contribute to the dystrophic pathology in models of Duchenne muscular dystrophy. ( Alves, FM; Ayton, S; Bush, AI; Caldow, MK; Chung, JD; Crouch, PJ; Hardee, JP; Hare, DJ; Koopman, R; Kysenius, K; Lynch, GS; Trieu, J, 2022) |
| "Chitogel in combination with Def 20 mM is safe and effective in decreasing the inflammatory process and may possibly reduce post-operative adhesions following laminectomy." | 1.56 | Prevention of peridural adhesions in spinal surgery: Assessing safety and efficacy of Chitogel with Deferiprone in a sheep model. ( Anne Fong, S; Bassiouni, A; Chryssidis, S; James Psaltis, A; Jukes, A; Mascarenhas, A; Moratti, S; Nguyen-Hoang, A; Otto, S; Patel, S; Richter, K; Vediappan, RS; Vreugde, S; Wormald, PJ, 2020) |
| "Pulmonary iron overload was induced in heterozygous β-globin knockout mice (muβth-3/+, BKO)." | 1.42 | Effects of Iron Chelators on Pulmonary Iron Overload and Oxidative Stress in β-Thalassemic Mice. ( Chaisri, U; Fucharoen, S; Hemstapat, W; Morales, NP; Srichairatanakool, S; Svasti, S; Wichaiyo, S; Yatmark, P, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alves, FM | 1 |
| Kysenius, K | 1 |
| Caldow, MK | 1 |
| Hardee, JP | 1 |
| Chung, JD | 1 |
| Trieu, J | 1 |
| Hare, DJ | 1 |
| Crouch, PJ | 1 |
| Ayton, S | 1 |
| Bush, AI | 1 |
| Lynch, GS | 1 |
| Koopman, R | 1 |
| Vediappan, RS | 1 |
| Mascarenhas, A | 1 |
| Nguyen-Hoang, A | 1 |
| Anne Fong, S | 1 |
| Jukes, A | 1 |
| Richter, K | 1 |
| Bassiouni, A | 1 |
| Patel, S | 1 |
| Chryssidis, S | 1 |
| Otto, S | 1 |
| Moratti, S | 1 |
| James Psaltis, A | 1 |
| Vreugde, S | 1 |
| Wormald, PJ | 1 |
| Pepe, A | 1 |
| Meloni, A | 1 |
| Filosa, A | 1 |
| Pistoia, L | 1 |
| Borsellino, Z | 1 |
| D'Ascola, DG | 1 |
| Lisi, R | 1 |
| Putti, MC | 1 |
| Allò, M | 1 |
| Gamberini, MR | 1 |
| Quarta, A | 1 |
| Fidone, C | 1 |
| Casini, T | 1 |
| Restaino, G | 1 |
| Midiri, M | 1 |
| Mangione, M | 1 |
| Positano, V | 1 |
| Casale, M | 1 |
| Yatmark, P | 1 |
| Morales, NP | 1 |
| Chaisri, U | 1 |
| Wichaiyo, S | 1 |
| Hemstapat, W | 1 |
| Srichairatanakool, S | 1 |
| Svasti, S | 1 |
| Fucharoen, S | 1 |
4 other studies available for deferiprone and Fibrosis
| Article | Year |
|---|---|
Iron overload and impaired iron handling contribute to the dystrophic pathology in models of Duchenne muscular dystrophy.
Topics: Animals; Deferiprone; Dystrophin; Ferritins; Fibrosis; Heme; Iron; Iron Chelating Agents; Iron Overl | 2022 |
Prevention of peridural adhesions in spinal surgery: Assessing safety and efficacy of Chitogel with Deferiprone in a sheep model.
Topics: Adult; Animals; Cicatrix; Deferiprone; Dura Mater; Epidural Space; Failed Back Surgery Syndrome; Fem | 2020 |
Prospective CMR Survey in Children With Thalassemia Major: Insights From a National Network.
Topics: Adolescent; Age Factors; beta-Thalassemia; Cardiomyopathies; Child; Deferiprone; Deferoxamine; Femal | 2020 |
Effects of Iron Chelators on Pulmonary Iron Overload and Oxidative Stress in β-Thalassemic Mice.
Topics: Animals; Antidotes; beta-Globins; beta-Thalassemia; Deferiprone; Deferoxamine; Dextrans; Female; Fib | 2015 |